Bone Marrow Transplantation

Papers
(The H4-Index of Bone Marrow Transplantation is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
When is a chimaera not a chimaera?100
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)83
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards80
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study77
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)75
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency63
Prognostic impact of histopathologic features including histological grading and immunohistochemistry-positive cell counts in cytomegalovirus-gastrointestinal disease after allogeneic hematopoietic ce60
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P919-P930)50
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma47
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study44
Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults40
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey39
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany39
CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma38
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China38
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from th35
Randomized phase 2 study of digital life coaching during transplantation for myeloma33
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia32
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease32
The effect of posttransplant cyclophosphamide on ocular graft-versus-host disease32
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status31
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen31
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma30
MRD-guided de-escalation of TBI conditioning in ALL30
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact30
Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the 29
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study28
CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy27
Cytokine release syndrome: implications for transplant outcomes in haploidentical and HLA-matched HSCT using PTCy27
Palliative care involvement for pediatric hematopoietic cell transplant patients can enhance comfort-focused care at end of life without shortening survival duration27
0.14362001419067